Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma

British Journal of Haematology

Volumn 128, Issue 2, 2005, Pages 177-183

  Korfel, Agnieszka ^a   Martus, Peter ^a   Nowrousian, Mohammad R ^b   Hossfeld, Dieter K ^c   Kirchen, Heinz ^d   Brücher, Joachim ^e   Stelljes, Matthias ^f   Birkmann, Josef ^g   Peschel, Christian ^h   Pasold, Rita ⁱ   Fischer, Lars ^a   Jahnke, Kristoph ^a   Thiel, Eckhard ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Medical Clinic I   (Germany)

^e KLINIKUM ASCHAFFENBURG   (Germany)

^f UNIVERSITY OF MÜNSTER   (Germany)

^g KLINIKUM NÜRNBERG   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ KLINIKUM ERNST VON BERGMANN   (Germany)

Author keywords

Chemotherapy; Primary central nervous system lymphoma; Radiotherapy; Survival; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CARMUSTINE; CYTARABINE; DEXAMETHASONE; FOLINIC ACID; HYDROCORTISONE; IDARUBICIN; IFOSFAMIDE; METHOTREXATE; PROCARBAZINE;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN LYMPHOMA; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL TRIAL; DRUG FATALITY; DRUG WITHDRAWAL; EVALUATION; HUMAN; INFECTION; LEUKOPENIA; LUNG TOXICITY; MULTICENTER STUDY; NAUSEA; NEPHROTOXICITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RELAPSE; STATISTICAL SIGNIFICANCE; STOMATITIS; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CENTRAL NERVOUS SYSTEM NEOPLASMS; COMBINED MODALITY THERAPY; DEXAMETHASONE; FEMALE; HUMANS; LEUCOVORIN; LYMPHOMA; MALE; METHOTREXATE; MIDDLE AGED; PROCARBAZINE; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 19944432944     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2004.05284.x     Document Type: Article

References (23)

1. Abrey, L.E., DeAngelis, L.M. & Yahalom, J. (1998) Long-term survival in primary CNS lymphoma. Journal of Clinical Oncology, 16, 859-863.
2. Abrey, L.E., Yahalom, J. & DeAngelis, L.M. (2000) Treatment for primary CNS lymphoma: the next step. Journal of Clinical Oncology, 18, 3144-3150.
3. Antman, K., Anato, D. & Wood, W. (1985) Selection bias in clinical trials. Journal of Clinical Oncology, 3, 1142-1147.
4. Bertino, J.R. (1986) Guidelines for reporting clinical trials (editorial). Journal of Clinical Oncology, 4, 1.
5. Blay, J.-Y., Bouhour, D., Carrie, C., Bouffet, E., Brunat-Mentigny, M., Philip, T. & Biron, P. (1995) The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin's lymphoma of patients with no known cause of immunossuppression. Blood, 86, 2922-2929.
6. Blay, J.Y., Conroy, T., Chevreau, C., Quesnel, N., Eghbali, H., Bouabdallah, R., Coiffier, B., Wagner, J.P., Le Mevel, A., Dramais-Marcel, D., Baumelou, E., Chauvin, F. & Biron, P. (1998) High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. Journal of Clinical Oncology, 16, 864-871.
7. DeAngelis, L., Seiferheld, W., Schold, S.C., Fisher, B., Schultz, C.J. & Radiation Therapy Oncology Study Group 93-10 (2002) Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: radiation therapy oncology group study 93-10. Journal of Clinical Oncology, 20, 4643-4648.
8. Ferreri, A.J.M., Reni, M. & Villa, E. (2000) Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Annals of Oncology, 11, 927-937.
9. Ferreri, A., Reni, M., Pasini, F., Calderoni, A., Tirelli, U., Pivnik, A., Aondio, G.M., Ferrarese, F., Gomez, H., Ponzoni, M., Borisch, B., Berger, F., Chassagne, G., Iuzzolino, P., Carbone; A., Weis, J., Pedrinis, E., Motta, T., Jouvet, A., Barbui, T., Cavalli, F. & Blay, J.Y. (2002) A multicenter study of treatment of primary CNS lymphoma. Neurology, 58, 1513-1520.
10. Ferreri, A.J., Blay, J.Y., Reni, M., Pasini, F., Spina, M., Ambrosetti, A., Calderoni, A., Rossi, A., Vavassori, V., Conconi, A., Devizzi, L., Berger, F., Ponzoni, M., Borisch, B., Tinguely, M., Cerati, M., Milani, M., Orvieto, E., Sanchez, J., Chevreau, C., Dell'Oro, S., Zucca, E. & Cavalli, F. (2003) Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. Journal of Clinical Oncology, 21, 266-272.
11. Hiraga, S., Arita, N., Ohnishi, T., Kohmura, E., Yamamoto, K., Oku, Y., Taki, T., Sato, M., Aozasa, K. & Yoshimine, T. (1999) Rapid infusion of high dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphoma. Journal of Neurosurgery, 91, 221-230.
12. Korfet, A. & Thiel, E. (1997) Successful treatment of Non-Hodgkin's lymphoma of the central nervous system with BMPD chemotherapy followed by radiotherapy. Leukemia and Lymphoma, 30, 609-617.
13. Levin, V.A., Silver, P., Hannigan, J., Wara, W.M., Gutin, P.H., Davis, R.L. & Wilson, C.B. (1990) Superiority of postradiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. International Journal of Radiation Oncology, Biology, and Physics, 18, 321-324.
14. MacDonald, D.R., Cascino, T.L., Schold, Jr, S.C. & Cairncross, J.G. (1990) Response criteria for phase II studies of supratentorial malignant glioma. Journal of Clinical Oncology, 8, 1277-1280.
15. Mead, G.M., Blechen, N.M., Gregor, A., Bullimore, J., Shirley, D., Rampling, R.P., Trevor, J., Glaser, M.G., Lantos, P., Ironside, J.W., Moss, T.H., Brada, M., Whaley, J.B. & Stenning, S.P. (2000) A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma: cerebral radiotherapy with and without cyclophoshamide, doxorubicin, vincristine, and prednisone chemotherapy. Cancer, 89, 1359-1370.
16. O'Brien, P., Roos, D., Pratt, G., Liew, K., Barton, M., Poulsen, M., Olver, I. & Trotter, G. (2000) Phase II multicenter study of brief single-agent methotrexate followed by irradiation in primary CNS lymphoma. Journal of Clinical Oncology, 18, 519-526.
17. O'Neill, B., Wang, C.-H. & O'Fallon, J. (1999) Primary central nervous system non-Hodgkin's lymphoma (PCNSL): survival advantages with combined initial therapy? A final report of the north central cancer treatment group (NCTG) study 86-72-52. International Journal of Radiation Oncology, Biology, and Physics, 43, 559-563.
18. Peterson, K. & DeAngelis, L.M. (1997) Primary cerebral lymphoma. In: Handbook of Clinical Neurology, vol 24: neuro-oncology, part II. (ed. by C.J. Vecht), pp. 257-268. Elsevier Science.
19. Poortmans, P.M.P., Kluin-Nelemans, H.C., Xaaxma-Reiche, H., Van't Veer, M., Hansen, M., Soubeyran, P., Taphoorn, M., Thomas, J., Van den Bent, M., Pickers, M., Van Imhoff, G., Rozewicz, C., Teodorovic, I. & van Glabbeke, M. & European Organization for Research and Treatment of Cancer Lymphoma Group (2003) High-dose methotrexate-based chemotherapy followed by consolidating radiotherapy in non-AIDS-related primary central nervous system lymphoma: European organisation for research and treatment of cancer lymphoma group phase II trial 20962. Journal of Clinical Oncology, 21, 4483-4488.
20. Reid, J.M., Pendergrass, T.W., Krailo, M.D., Hammond, G.D. & Ames, MM. (1990) Plasma pharmacokinetics and cerebrospinal fluid concentration of idarubicin and idarubicinol in pediatric leukemia patients: a children's cancer study group report. Cancer Research, 50, 6525-6528.
21. Schultz, C., Scott, C., Sherman, W., Donahue, B., Fields, J., Murray, K., Fisher, B., Abrams, R. & Meis-Kindblom, J. (1996) Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06. Journal of Clinical Oncology, 14, 556-564.
22. Tetef, M.L., Margolin, K.A., Doroshow, J.H., Akman, S., Leong, L.A., Morgan, Jr, R.J., Raschko, J.W., Slatkin, N., Somlo, G., Longmate, J.A., Carroll, M.I. & Newman, E.M. (2000) Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. Cancer Chemotherapy Pharmacology., 46, 19-26.
23. Yule, S.M., Price, L., Pearson, A.D.J. & Boddy, A., (1997) Cyclophosphamide and ifosfamide metabolites in the cerebrospinal fluid of children. Clinical Cancer Research, 3, 1985-1992.